ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

EMFLAZA ORAL SUSPENSION
Miscellaneous musculoskeletal disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

EMFLAZA ORAL SUSPENSION Rx

Generic Name and Formulations:
Deflazacort 22.75mg/mL; contains benzyl alcohol.

Company:
PTC Therapeutics, Inc.

Therapeutic Use:

Indications for EMFLAZA ORAL SUSPENSION:

Duchenne muscular dystrophy (DMD).

Adults and Children:

<5yrs: not recommended. Use oral dispenser. Slowly add into 3–4oz of juice or milk (avoid grapefruit juice). ≥5yrs: 0.9mg/kg once daily. Round to the nearest tenth of a milliliter (mL). Concomitant moderate or strong CYP3A4 inhibitors (eg, clarithromycin, fluconazole, diltiazem, verapamil): give ⅓ dose.

Warnings/Precautions:

Increased risk of infection (eg, viral, bacterial, fungal, protozoan, helminthic) and may mask signs/symptoms. If exposed to chickenpox or measles, consider prophylactic passive immune therapy. Concomitant systemic fungal infections, active ocular herpes simplex: not recommended. Hepatitis B virus reactivation. Latent or acute amebiasis. Strongyloides infestation. Cushing’s syndrome. Hyperglycemia. Thyroid disorders. Hypopituitarism. Adrenal insufficiency. Congenital adrenal hyperplasia. Pheochromocytoma. Supplement with additional steroids during physiologic stress. CHF. Hypertension. Recent MI. Renal insufficiency. Peptic ulcers. Diverticulitis. Intestinal anastomoses. Ulcerative colitis. Psychotic tendencies. Myasthenia gravis. Thromboembolic disorders. Risk of osteoporosis; monitor bone mineral density with long-term therapy. Discontinue at the first sign of rash. Avoid abrupt cessation. Monitor weight, growth, BP, fluid, electrolyte balance, blood glucose, and intraocular pressure (w. therapy >6weeks). Oral susp: neonates/infants (gasping syndrome). Pregnancy. Nursing mothers.

Interactions:

See Adults and Children. Live or live attenuated vaccines: not recommended; may get suboptimal response. Avoid concomitant moderate or strong CYP3A4 inducers (eg, efavirenz, carbamazepine, phenytoin). Concomitant levothyroxine: give corticosteroid first. May need to adjust dose of antidiabetic agents. Increased risk of acute myopathy with concomitant neuromuscular blockers (eg, pancuronium).

See Also:

EMFLAZA

Pharmacological Class:

Corticosteroid.

Adverse Reactions:

Cushingoid appearance, weight increase, increased appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, nasopharyngitis; HPA axis suppression, steroid withdrawal syndrome, avascular necrosis, GI perforation, behavioral/mood changes, glaucoma, cataracts, myopathy, Kaposi's sarcoma, anaphylaxis, negative growth/development effects (in children).

Generic Availability:

NO

How Supplied:

Tabs 6mg—100; 18mg, 30mg, 36mg—30; Oral susp—13mL (w. oral dispensers)

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs